A Phase 1, Single-Center, Open-label Study to Evaluate the Safety and Pharmacokinetics of Two Tablet Formulations of PRN1008 in healthy adult volunteers.
Latest Information Update: 16 Jul 2019
At a glance
- Drugs Rilzabrutinib (Primary)
- Indications Autoimmune disorders; Pemphigus vulgaris
- Focus Pharmacokinetics
- Sponsors Principia Biopharma
- 15 Nov 2016 New trial record